Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:DVAX NASDAQ:LGND NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$35.26+3.4%$32.06$19.52▼$35.79$2.68B0.95943,542 shs4.79 million shsDVAXDynavax Technologies$15.50$15.51$9.20▼$15.73$1.82B0.972.20 million shsN/ALGNDLigand Pharmaceuticals$303.59+2.6%$238.60$111.71▼$305.71$6.08B1.17398,062 shs1.25 million shsRGENRepligen$147.01+1.2%$122.84$100.99▼$175.77$8.29B1.09965,300 shs1.97 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+3.43%+8.73%+11.41%+16.37%+64.31%DVAXDynavax Technologies0.00%0.00%0.00%0.00%+57.20%LGNDLigand Pharmaceuticals+2.59%+10.44%+28.70%+55.30%+162.35%RGENRepligen+1.23%+11.35%+29.90%+33.50%+18.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$35.26+3.4%$32.06$19.52▼$35.79$2.68B0.95943,542 shs4.79 million shsDVAXDynavax Technologies$15.50$15.51$9.20▼$15.73$1.82B0.972.20 million shsN/ALGNDLigand Pharmaceuticals$303.59+2.6%$238.60$111.71▼$305.71$6.08B1.17398,062 shs1.25 million shsRGENRepligen$147.01+1.2%$122.84$100.99▼$175.77$8.29B1.09965,300 shs1.97 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics+3.43%+8.73%+11.41%+16.37%+64.31%DVAXDynavax Technologies0.00%0.00%0.00%0.00%+57.20%LGNDLigand Pharmaceuticals+2.59%+10.44%+28.70%+55.30%+162.35%RGENRepligen+1.23%+11.35%+29.90%+33.50%+18.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.82Moderate Buy$49.3039.82% UpsideDVAXDynavax Technologies 2.00Hold$32.00106.45% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.71-15.11% DownsideRGENRepligen 2.88Moderate Buy$164.6411.99% UpsideCurrent Analyst Ratings BreakdownLatest DVAX, RGEN, LGND, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026CLDXCelldex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/10/2026CLDXCelldex Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $45.006/3/2026RGENRepligen HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$170.00 ➝ $150.006/2/2026RGENRepligen Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.006/1/2026RGENRepligen Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$160.005/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/8/2026LGNDLigand Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$252.00 ➝ $262.00(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$865K3,199.57N/AN/A$7.93 per share4.45DVAXDynavax Technologies$330.51M5.51$0.16 per share97.88$4.54 per share3.41LGNDLigand Pharmaceuticals$274.48M22.17$8.05 per share37.69$51.68 per share5.87RGENRepligen$763.34M10.86$3.46 per share42.50$37.42 per share3.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)DVAXDynavax Technologies$27.31M-$0.37N/A31.63N/A-13.13%7.18%4.08%N/ALGNDLigand Pharmaceuticals$124.45M$7.3741.1936.673.3155.95%16.19%11.13%8/6/2026 (Estimated)RGENRepligen$48.89M$0.90163.3560.502.806.73%4.88%3.48%8/4/2026 (Estimated)Latest DVAX, RGEN, LGND, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/7/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/5/2026Q1 2026RGENRepligen$0.38$0.48+$0.10$0.15$192.05 million$194.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A8.928.92DVAXDynavax Technologies0.417.626.94LGNDLigand Pharmaceuticals0.4521.2820.95RGENRepligen0.269.207.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/ADVAXDynavax Technologies96.96%LGNDLigand Pharmaceuticals91.28%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics5.20%DVAXDynavax Technologies2.98%LGNDLigand Pharmaceuticals7.00%RGENRepligen0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableDVAXDynavax Technologies350117.43 million113.93 millionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableRGENRepligen2,00056.41 million56.07 millionOptionableDVAX, RGEN, LGND, and CLDX HeadlinesRecent News About These CompaniesInsider Selling: Repligen (NASDAQ:RGEN) CFO Sells 733 Shares of StockJune 27 at 6:21 AM | insidertrades.comWasatch Advisors LP Purchases New Position in Repligen Corporation $RGENJune 27 at 5:35 AM | marketbeat.com2 high-flying stocks on our watchlist and 1 we find riskyJune 25 at 6:14 PM | msn.comRepligen jumps as investors revisit strong Q1 results and bioprocessing recovery outlookJune 24 at 5:50 PM | quiverquant.comQRepligen Corporation (RGEN) Dropped Following the Earnings ReleaseJune 24 at 10:31 AM | insidermonkey.comRepligen (RGEN) Dropped Following the Earnings ReleaseJune 24 at 10:10 AM | finance.yahoo.comRepligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells InvestorsJune 22, 2026 | gurufocus.comRepligen Corporation (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 21, 2026 | americanbankingnews.com2 Profitable Stocks on Our Watchlist and 1 Facing ChallengesJune 19, 2026 | finance.yahoo.comRepligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences ToolsJune 19, 2026 | finance.yahoo.comRBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its ViewJune 12, 2026 | insidermonkey.comRepligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Tells InvestorsJune 9, 2026 | gurufocus.comRepligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?June 4, 2026 | zacks.comRepligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 4, 2026 | seekingalpha.comRepligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference TranscriptJune 3, 2026 | seekingalpha.comRepligen Has A Cleaner Recovery Angle, But With High ValuationMay 31, 2026 | seekingalpha.comRepligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF Score: 79/100May 28, 2026 | gurufocus.comGuggenheim Reaffirms Their Hold Rating on Repligen (RGEN)May 25, 2026 | theglobeandmail.comRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceMay 22, 2026 | globenewswire.comRepligen Announces Publication of the Company’s 2025 Corporate Sustainability ReportMay 20, 2026 | markets.businessinsider.comRepligen Announces Publication of the Company's 2025 Corporate Sustainability ReportMay 20, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Washington’s Quantum Push Puts IBM and IonQ on the ThroneBy Jeffrey Neal Johnson | June 25, 2026European Banks Are Outperforming : Can These 3 Keep It Going?By Dan Schmidt | June 25, 2026DVAX, RGEN, LGND, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$35.26 +1.17 (+3.43%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$32.89 -2.37 (-6.72%) As of 06/26/2026 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Dynavax Technologies NASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Ligand Pharmaceuticals NASDAQ:LGND$303.59 +7.67 (+2.59%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$284.00 -19.59 (-6.45%) As of 06/26/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Repligen NASDAQ:RGEN$147.01 +1.78 (+1.23%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$148.01 +1.01 (+0.68%) As of 06/26/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
